Most Read Articles
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.

Docetaxel with concurrent radiotherapy safe in most elderly oesophageal cancer patients

17 May 2020
Looking into 2018, Singapore has a few plans in mind to improve healthcare for the public, especially the elderly.

Concurrent docetaxel with radiotherapy (DOC-RT) is generally safe in elderly patients with oesophageal cancer (EC), though caution should be advised in the very old and undernourished, a recent study has shown.

The study included 84 older EC patients (median age, 80 years; 84 percent male) who underwent radiotherapy at 60 Gy in 30 fractions. Participants also received concurrent DOC treatment at 10 mg/m2 per week for six cycles. Outcomes included survival, toxicity and treatment completion.

Over a median follow-up of 14 months, majority of the patients died. Forty deaths were attributable to tumour progression. The remaining 27 survivors were followed for a median of 24 months. The resulting 1-, 3- and 5-year progression-free survival (PFS) rates were 41 percent, 24 percent and 8 percent, respectively.

At the same time points, the corresponding overall survival (OS) estimates were 63 percent, 33 percent and 13 percent. The median survival time was 21 months.

Sixty-five participants completed DOC-RT, yielding a completion rate of 89 percent. Discontinuations were due to deterioration of general condition, oesophageal fistulae, pneumonia and pain. Noncompleters were significantly more likely to be very old (p<0.001), at least 80 years of age, and undernourished (p=0.004), with geriatric nutritional risk index scores <92.

None of the other baseline factors, including sex, clinical stage, smoking status and treatment factors, affected completion rate.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.